Structural and electronic structure differences due to the O–H···O and O–H···S bond formation in selected benzamide derivatives: a first-principles molecular dynamics study

被引:0
作者
Aneta Jezierska
Jarosław J. Panek
Riccardo Mazzarello
机构
[1] National Institute of Chemistry,Faculty of Chemistry
[2] University of Wrocław,Computational Science, Department of Chemistry and Applied Biosciences
[3] ETH Zurich,undefined
来源
Theoretical Chemistry Accounts | 2009年 / 124卷
关键词
Intramolecular hydrogen bond; Atoms in molecules; Car–Parrinello molecular dynamics (CPMD); Path integrals molecular dynamics (PIMD);
D O I
暂无
中图分类号
学科分类号
摘要
Density functional theory-based methods were employed to obtain static and dynamical descriptions of the molecular properties of 2-hydroxy-N-methylbenzamide and 2-hydroxy-N-methylthiobenzamide; compounds containing O–H···O and O–H···S strong, intramolecular hydrogen bonds. These compounds are important as analogues of commercial analgesic and antipyretic medicines. In the current study the classical Kohn–Sham method was applied to develop static models describing the geometric parameters and proton potentials. The topological analysis of the electron density was performed via atoms in molecules theory. Subsequently, Car–Parrinello molecular dynamics investigations were performed in vacuo and in the solid state. The geometric and spectroscopic properties were investigated and compared with available experimental data. The influence of quantum effects on the intramolecular hydrogen bond properties were studied via path integral molecular dynamics in the solid state for 2-hydroxy-N-methylbenzamide. We found that the proton behavior depends strongly on the type of acceptor: the sulfur-containing bridge has significantly smaller proton flexibility than the oxygen-bearing analogue, which is reflected in the electronic structure and bridge dynamics.
引用
收藏
页码:319 / 330
页数:11
相关论文
共 188 条
[1]  
Soldatos CR(1978)undefined Pharmacol 16 193-198
[2]  
Kales A(1953)undefined J Pharmacol Exp Ther 108 450-460
[3]  
Bixler EO(2006)undefined Br J Pharmacol 149 551-559
[4]  
Scharf MB(2006)undefined Cancer Sci 97 84-89
[5]  
Kales JD(1984)undefined Pharmazie 39 373-378
[6]  
Way EL(2008)undefined Bioorg Med Chem 16 8760-8764
[7]  
Takemori AE(1966)undefined Pharmazie 21 161-166
[8]  
Smith GE(1966)undefined Pharmazie 21 477-482
[9]  
Anderson HH(1971)undefined Anal Chim Acta 57 201-208
[10]  
Brodie DC(1972)undefined Anal Chim Acta 59 306-310